Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Joseph T Hull"'
Autor:
Hadassa Klerman, Melissa A St Hilaire, Richard E Kronauer, Joshua J Gooley, Claude Gronfier, Joseph T Hull, Steven W Lockley, Nayantara Santhi, Wei Wang, Elizabeth B Klerman
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e33836 (2012)
Accurate determination of circadian phase is necessary for research and clinical purposes because of the influence of the master circadian pacemaker on multiple physiologic functions. Melatonin is presently the most accurate marker of the activity of
Externí odkaz:
https://doaj.org/article/90d45da9d226434496728e9c214e4b16
Autor:
Stephen V. Faraone, Roberto Gomeni, Joseph T. Hull, Gregory D. Busse, Brendan Lujan, Jonathan Rubin, Azmi Nasser
Publikováno v:
Brain and Behavior, Vol 13, Iss 4, Pp n/a-n/a (2023)
Abstract Introduction Attention‐deficit/hyperactivity disorder (ADHD) is associated with impairments related to peer relations (PR) and social activities (SA). The objective of this post hoc analysis was to assess the degree to which viloxazine ext
Externí odkaz:
https://doaj.org/article/afdd2782a9f94fd49c7e985f39cbdc3d
Autor:
Ciaran J. McMullan, Andrew W. McHill, Joseph T. Hull, Wei Wang, John P. Forman, Elizabeth B. Klerman
Publikováno v:
Frontiers in Physiology, Vol 13 (2022)
Prolonged exposure to chronic sleep restriction (CSR) and shiftwork are both associated with incident hypertension and cardiovascular disease. We hypothesized that the combination of CSR and shiftwork’s rotating sleep schedule (causing recurrent ci
Externí odkaz:
https://doaj.org/article/0dd8dc263d0e424aace0115dfeb3e54d
Autor:
Azmi Nasser, Joseph T. Hull, Tesfaye Liranso, Nicholas Fry, Andrew J. Cutler, Jonathan Rubin, Ann Childress
Publikováno v:
CNS Drugs. 36:1333-1335
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9974b3fb45188efefda66cced5a6e7e2
https://doi.org/10.1007/s40263-022-00967-5
https://doi.org/10.1007/s40263-022-00967-5
Autor:
Azmi Nasser, Roberto Gomeni, Zhao Wang, Joseph T. Hull, Gregory D. Busse, Zare Melyan, Maurizio Fava, Welton O'Neal, Jonathan Rubin
Publikováno v:
British Journal of Clinical Pharmacology. 88:4828-4838
Four Phase 3 studies evaluated efficacy and safety of viloxazine extended-release in the treatment of attention-deficit/hyperactivity disorder (ADHD). The primary efficacy objective-change from baseline in ADHD Rating Scale-5 (ADHD-RS-5) Total score
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87eb01ef7dfd14ca68bd714ca9cc1445
https://doi.org/10.1111/bcp.15412
https://doi.org/10.1111/bcp.15412
Publikováno v:
Frontiers in Endocrinology, Vol 9 (2018)
Weight gain and obesity have reached epidemic proportions in modern society. Insufficient sleep—which is also prevalent in modern society—and eating at inappropriate circadian times have been identified as risk factors for weight gain, yet the im
Externí odkaz:
https://doaj.org/article/d41efd8c5c5046a78648f8dc4050543b
Autor:
null Stephen V. Faraone, null Roberto Gomeni, null Joseph T. Hull, null Gregory D. Busse, null Brendan Lujan, null Jonathan Rubin, null Azmi Nasser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e042ba22fc2bdb9a49e6692293b83c4c
https://doi.org/10.1002/brb3.2910/v2/response1
https://doi.org/10.1002/brb3.2910/v2/response1
Autor:
Stephen V. Faraone, Gregory D. Busse, Jonathan Rubin, Zare Melyan, Azmi Nasser, Roberto Gomeni, Joseph T. Hull
Publikováno v:
European Child & Adolescent Psychiatry. 32:491-499
Improvement in attention-deficit/hyperactivity disorder (ADHD) symptoms vs. placebo was reported in a series of pediatric clinical trials of viloxazine extended-release capsules (viloxazine ER; Qelbree™). This post hoc analysis of those studies eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::062ca8548c04d24f6fdd1fc3e1444fc3
https://doi.org/10.1007/s00787-021-01877-5
https://doi.org/10.1007/s00787-021-01877-5
Autor:
Roberto Gomeni, Stephen V. Faraone, Zare Melyan, Gregory D. Busse, Azmi Nasser, Joseph T. Hull, Jonathan Rubin
Publikováno v:
Paediatric Drugs
Aim The aim of this study was to evaluate the effect of viloxazine extended-release capsules (viloxazine ER; Qelbree™) on executive function deficits (EFDs) in pediatric subjects (6–17 years of age) with attention-deficit/hyperactivity disorder (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::218467e7f321af02d8582af39c48b01b
https://doi.org/10.1007/s40272-021-00470-2
https://doi.org/10.1007/s40272-021-00470-2
Autor:
Robert L. Findling, Azmi Nasser, Gregory D. Busse, Nicholas Fry, Nandita Joshi Jones, Tesfaye Liranso, Joseph T. Hull, Fatima Chowdhry, Andrew J. Cutler, Toyin Adewole, Stefan Schwabe
Publikováno v:
Journal of Clinical Psychopharmacology
Supplemental digital content is available in the text.
Purpose This phase 3 clinical trial evaluated the efficacy and safety of viloxazine extended-release capsules (VLX-ER) as a monotherapy for attention-deficit/hyperactivity disorder (ADHD) in
Purpose This phase 3 clinical trial evaluated the efficacy and safety of viloxazine extended-release capsules (VLX-ER) as a monotherapy for attention-deficit/hyperactivity disorder (ADHD) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8cef5f15b26f8894ce420a97cff7429
https://doi.org/10.1097/jcp.0000000000001404
https://doi.org/10.1097/jcp.0000000000001404